OQROGet OQRO Pro
Insider trade

Corcept Therapeutics (CORT)CEO sold ~$1.31M

Joseph K Belanoff, CEO at Corcept Therapeutics, sold ~$1.31M of Corcept Therapeutics shares.

~$1.31M
Approx. value · 26K sh @ $50.07
2.92M
Holds after · shares reported
Traded
Mar 25, 2026
Filed
Mar 28, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 3, 2026InsiderOfficer sold ~$817K of CORT shares in the open market
  2. Feb 24, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  3. Mar 4, 2026InsiderOfficer sold ~$296K of CORT shares in the open market
  4. Mar 17, 2026Insider · 1 personInsiders: 2 purchases (~$3.3M)
  5. Mar 20, 2026InsiderOfficer sold ~$424K of CORT shares in the open market
  6. Mar 25, 2026 · this disclosureInsiderCEO sold ~$1.31M of CORT shares in the open market

What came next

  1. Apr 7, 2026InsiderOfficer sold ~$819K of CORT shares in the open market
  2. Apr 30, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  3. May 1, 2026InsiderCEO sold ~$2M of CORT shares in the open market
  4. May 5, 2026InsiderOfficer sold ~$1.04M of CORT shares in the open market
  5. May 21, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 21, 2026, Corcept Therapeutics Incorporated (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
  6. May 27, 2026Insider · 2 peopleInsiders: 3 sales (~$5.2M)
  7. Jun 1, 2026Insider · 3 peopleInsiders: 4 sales (~$5.5M)
  8. Jun 2, 2026InsiderOfficer sold ~$1.41M of CORT shares in the open market
  9. Jun 15, 2026Insider · 1 personInsiders: 4 sales (~$3.2M)
  10. Jun 16, 2026Insider · 1 personInsiders: 2 sales (~$832K)
  11. Jun 17, 2026InsiderDirector sold ~$1.69M of CORT shares in the open market
  12. Jul 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
  13. Jul 7, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
  14. Jul 15, 2026Insider · 2 peopleInsiders: 8 sales (~$4.4M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Corcept Therapeutics

For Corcept Therapeutics, OQRO holds 64 insider filings (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CORT page.

Other recent filings by Joseph K Belanoff, Chief Executive Officer

The full history of Joseph K Belanoff, Chief Executive Officer is on the profile page.

How this filing works

Other disclosures at Corcept Therapeutics

Everything OQRO holds on this company is on its CORT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data